Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia-Reference-Cited by-同舟云学术

Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia

Published:2009-04-02 Issue:6 Volume:23 Page:1062-1072
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Rossi D,Lobetti Bodoni C,Genuardi E,Monitillo L,Drandi D,Cerri M,Deambrogi C,Ricca I,Rocci A,Ferrero S,Bernocco E,Capello D,De Paoli L,Bergui L,Boi M,Omedè P,Massaia M,Tarella C,Passera R,Boccadoro M,Gaidano G,Ladetto M

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2008399.pdf

Reference50 articles.

1. Binet JL, Caligaris-Cappio F, Catovsky D, Cheson B, Davis T, Dighiero G et al. Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. Blood 2006; 107: 859–861.

2. Ghia P, Ferreri AM, Caligaris-Cappio F . Chronic lymphocytic leukemia. Crit Rev Oncol Hematol 2007; 64: 234–246.

3. Dighiero G, Hamblin TJ . Chronic lymphocytic leukaemia. Lancet 2008; 371: 1017–1029.

4. Moreno C, Montserrat M . New prognostic markers in chronic lymphocytic leukemia. Blood Rev 2008; 22: 211–219.

5. Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910–1916.

Cited by 84 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genetically predicted telomere length and the risk of 11 hematological diseases: a Mendelian randomization study;Aging;2024-02-22

2. Proliferative History Is a Novel Driver of Clinical Outcome in Splenic Marginal Zone Lymphoma;2024-01-17

3. Immunophenotypic and genomic landscape of Richter transformation diffuse large B-cell lymphoma;Pathology;2023-06

4. Biomarkers of ageing: Current state‐of‐art, challenges, and opportunities;MedComm – Future Medicine;2023-06

5. In silico investigations identified Butyl Xanalterate to competently target CK2α (CSNK2A1) for therapy of chronic lymphocytic leukemia;Scientific Reports;2022-10-21